CymaBay Therapeutics to Present at Two Upcoming Investor Conferences in March
NEWARK, Calif., March 03, 2016 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq:CBAY), a clinical-stage biopharmaceutical company developing therapies to treat metabolic diseases with high unmet medical need, today announced that Harold Van Wart, Ph.D., President and Chief Executive Officer, will present a corporate update at the Cowen and Company 36th Annual Health Care Conference on Wednesday, March 9 and at the 28th Annual ROTH Conference on Wednesday, March 16.
|
Cowen and Company 36th Annual Health Care Conference | |||||
| Date: | Wednesday, March 9 | ||||
| Time: | 9:20am – 9:50am Eastern Time | ||||
| Place: | Boston Marriott Copley Place, Boston, MA | ||||
| Webcast: | http://ir.cymabay.com/events | ||||
| 28th Annual ROTH Conference | |||||
| Date: | Wednesday, March 16 | ||||
| Time: | 10:00am – 10:30am Pacific Time | ||||
| Place: | The Ritz Carlton, Orange County, CA | ||||
About CymaBay
CymaBay Therapeutics, Inc. (CBAY) is a clinical-stage biopharmaceutical company developing therapies to treat metabolic diseases with high unmet medical need, including serious rare and orphan disorders. Arhalofenate is a potential Urate-Lowering Anti-Flare Therapy that has completed five Phase 2 studies in gout patients. Arhalofenate has been found to reduce painful flares in joints while at the same time promoting excretion of uric acid by the kidney. This dual action addresses both the signs and symptoms of gout while managing the underlying pathophysiology of hyperuricemia. MBX-8025 is a potent, selective, orally active PPARδ agonist. A Phase 2 study of MBX-8025 in patients with mixed dyslipidemia established that it has an anti-atherogenic lipid profile. CymaBay has two ongoing clinical studies for MBX-8025 including a pilot Phase 2 study in patients with homozygous familial hypercholesterolemia and a Phase 2 study in patients with primary biliary cholangitis.
For additional information about CymaBay visit www.cymabay.com.
Contact: Sujal Shah CymaBay Therapeutics, Inc. (510) 293-8800 Investors@CymaBay.com Hans Vitzthum LifeSci Advisors, LLC 212-915-2568 Hans@LifeSciAdvisors.com
Released March 3, 2016